Triple-Negative Breast Cancer makes up about 10-20% of breast cancer diagnoses and is more aggressive than other breast cancer types. Which means it has a worse prognosis. It’s also more common among younger women, black and Hispanic women, and those with the BRCA1 mutation.
Battling Triple Negative Breast Cancer is difficult because there are no targeted therapies currently available for its treatment, leaving a gaping void that needs to be addressed with utmost urgency.
Luckily, there are talented scientists working to change that.
But first – what is Triple-negative breast cancer?
It is a kind of breast cancer that does not have any of the receptors that are commonly found in breast cancer. Think of cancer cells as a baseball diamond with runners on. There are three bases, called receptors:
- One is for the female hormone estrogen.
- One is for the female hormone progesterone.
- One is a protein called human epidermal growth factor.
If your cancer is heading to any of these three bases, doctors have a few options (like hormone therapy or other drugs) to tag out the cancer and help destroy the cancer cells.
But if you have triple-negative breast cancer, it means those three bases aren’t loaded. So doctors have fewer “plays to make” for treatment.
So what can be done?
Meet Rakhee Gupte, MS, Ph.D., President & CEO of Raadysan Biotech, Inc., a biotechnology company involved in the Research & Development of highly differentiated therapies for Triple Negative Breast Cancer.
Dr. Gupte has over 20 years of academic (microbiology, biochemistry, molecular, and cell biology & immunology) and pharmaceutical experience. She has identified several novel signaling pathways in oncology and cardiovascular diseases that led to the discoveries of unique molecular targets for therapeutic intervention. She holds 5 US patents and has published over 20 abstracts and 18 full-length publications in peer-reviewed scientific journals.
As part of our “Save Second Base” series on breast cancer, we were thrilled to speak with Dr. Gupte about her company’s drug leads.
Raadysan’s drug leads offer the following benefits:
- It’s the first targeted therapy for Triple Negative Breast Cancer.
- It directly targets DNA replication/cell proliferation machinery.
- It will not directly damage the DNA, as observed with other conventional anti-cancer drugs, thus minimizing cell toxicity, and improving patient survival rates.
- It is receptor-independent and hence will be an effective therapy for all types of breast cancer.
- It inhibits cancer cell viability by 95%.
- It causes cancer cell death.
- It selectively targets only cancer cells.
You can check out the full interview below!